このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

中等度アルツハイマー病の参加者におけるSNK01の第I/IIa相研究

2026年9月29日 更新者:NKGen Biotech, Inc.

第 I/IIa 相、中等度アルツハイマー病の参加者における SNK01 の安全性、忍容性、探索的有効性を評価する研究

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:

  1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion
  2. Can SNK01 administration improve cognitive assessment scores and biomarkers

調査の概要

状態

募集

条件

介入・治療

研究の種類

介入

入学 (推定)

36

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • Glendale、California、アメリカ、91206
        • 募集
        • Behavioral Research Specialists, LLC
        • コンタクト:
      • Santa Ana、California、アメリカ、92705
        • 募集
        • Syrentis Clinical Research
        • コンタクト:
      • Tarzana、California、アメリカ、91356
        • 引きこもった
        • Valiance Clinical Research
    • Florida
      • Maitland、Florida、アメリカ、32751
        • 募集
        • K2 Medical Research
        • コンタクト:
      • Orlando、Florida、アメリカ、32804
    • New Jersey
      • Newark、New Jersey、アメリカ、07107
        • 募集
        • Rutgers Health
        • コンタクト:
    • New York
      • Albany、New York、アメリカ、12208
        • 募集
        • Alzheimer's Disease Research Center
        • コンタクト:
    • Ontario
      • Ottawa、Ontario、カナダ、K1Z 1G3
        • 引きこもった
        • Ottawa Memory Clinic

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the participant).

  2. Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site. The study partner/caregiver must sign a separate informed consent form which describes their contributions during the study.

  3. Patients with diagnosis of Alzheimer's dementia according to the recommendations from the 2011 National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

  4. Age 40 to 85 years old.

  5. Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient or their legally authorized representative and documented by the study investigator.

  6. Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Visit 1 before first administration of the study drug. Females of childbearing potential are defined as those who are not surgically sterile or who are not post-menopausal (i.e.: no menses for at least 1 year). Male and female participants of reproductive potential must also agree to abstinence or use acceptable form(s) of effective contraception during the study and for 30 days after the final dose of the study drug. Acceptable methods of contraception include the following:

    1. Condoms, sponges, foams, gels, diaphragms, or intrauterine device (IUD).
    2. Hormonal birth control for 30 days prior to administration of the study drug.
    3. A vasectomized sexual partner.
  7. Positive evidence for a diagnosis of AD via amyloid positron emission tomography (Amyloid PET) of the brain within the past six months.

  8. CDR-SB score of ≥ 9.5 and <16.0.

Exclusion Criteria:

  1. Substantial concomitant cerebrovascular disease defined as Fazekas Grade 3.
  2. History of a stroke/intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment in the opinion of the investigator.
  3. Any substance use disorder that has not been in remission for at least 12 months
  4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
  5. Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without oedema), tachycardia, arrhythmias, uncontrolled hypertension.
  6. History of cerebrovascular accident or transient ischemic attack (TIA), or unexplainable loss of consciousness within the last year.
  7. Significant pulmonary disease predisposing to hypoxia.
  8. Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinically significant heart disease classified as NYHA III or IV.
  9. Significant liver disease (for example cirrhosis, active hepatitis B and C, primary or metastatic liver neoplasm).
  10. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening.
  11. Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
  12. Immunological disorder such as per investigator judgement clinically significant allergies, Lupus erythematodes, or scleroderma.
  13. Uncontrolled/Unstable hematological disease (regardless of cause) such as refractory anemia or refractory myelosuppression.
  14. Neurological disease (such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, multiple sclerosis) and psychiatric disorders (such as schizophrenia, or intellectual disability), or any other disorders impacting cognitive function.
  15. Unstable/uncontrolled major depression or anxiety within the last 12 months.
  16. History of seizures in the past three years.
  17. Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or manifest hyperthyroidism, in the opinion of the investigator.
  18. Severe renal impairment defined as a GFR < 30 mL/min/1.73 m2 in the screening lab report
  19. Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any other infection or active systemic disease.
  20. Currently being treated with anticoagulants (except aspirin at or below a prophylactic dose).
  21. Participants who are taking medications for AD, like memantine or acetylcholinesterase inhibitors (AChEI) that exceeds the normal recommended dose range or have not achieved a stable dose for the 30 days prior to enrollment.
  22. Any contraindication for performing a brain MRI and/or Amyloid PET scan.
  23. Any participant whose safety the investigator considers to be at risk from this trial's intervention.
  24. Participants with any medically unstable/uncontrolled conditions.
  25. Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
  26. Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:SNK01

SNK01 will be administered as an IV infusion Q3W for up to 1 year.

SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

プラセボコンパレーター:Placebo

Placebo will be administered as an IV infusion Q3W for up to 1 year.

Sodium Lactate Hartmann's Solution

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of participants with dose-limiting toxicity
時間枠:3 weeks

DLTs will be assessed by the review of labs, PE and AEs

3 weeks
Maximum tolerated dose determination
時間枠:3 weeks

Determine the maximum tolerated dose based on the evaluation of the number of participants who experience a DLT which will then determine the RP2D.

3 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
時間枠:1 Year

Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs

1 Year
Preliminary efficacy in cognitive assessment scores of CDR-SB
時間枠:1 Year

Measure changes in cognitive assessment of CDR-SB from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of MMSE
時間枠:1 Year

Measure changes in cognitive assessment of MMSE from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of NPI
時間枠:1 Year

Measure changes in cognitive assessment of NPI from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of ADCS-ADL-Severe
時間枠:1 Year

Measure changes in cognitive assessment of ADCS-ADL-Severe from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of ADAS-Cog
時間枠:1 Year

Measure changes in cognitive assessment of ADAS-Cog from baseline

1 Year

二次結果の測定

結果測定
メジャーの説明
時間枠
Changes in CSF biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
時間枠:1 Year

Measure changes in CSF biomarkers as changed from baseline

1 Year
Changes in plasma biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
時間枠:1 Year

Measure changes in Plasma biomarkers as changed from baseline

1 Year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年11月21日

一次修了 (推定)

2028年3月1日

研究の完了 (推定)

2028年6月1日

試験登録日

最初に提出

2023年12月6日

QC基準を満たした最初の提出物

2024年1月2日

最初の投稿 (実際)

2024年1月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • SNK01-AD01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。